AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.205
+0.045 (1.08%)
Sep 5, 2025, 3:37 PM - Market open
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $17.08M in the quarter ending June 30, 2025, with 133.29% growth. This brings the company's revenue in the last twelve months to $32.88M, down -0.54% year-over-year. In the year 2024, AbCellera Biologics had annual revenue of $28.83M, down -24.17%.
Revenue (ttm)
$32.88M
Revenue Growth
-0.54%
P/S Ratio
37.54
Revenue / Employee
$55,161
Employees
596
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ABCL News
- 9 days ago - AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 23 days ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 4 weeks ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire
- 2 months ago - AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 3 months ago - AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 4 months ago - AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - Business Wire
- 4 months ago - AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire